Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome.

Kidney360·2023
Same author

Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study.

Gastroenterology·2023
Same author

Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2023
Same author

Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2023
Same author

Noninvasive Assessment of Liver Fibrosis in NAFLD.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2023
Same author

Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2023
Same journal

Decoding fibrosis: Transcriptomic and clinical insights via AI-derived collagen deposition phenotypes in MASLD.

Hepatology (Baltimore, Md.)·2026
Same journal

A randomized controlled trial of stepped treatment to reduce unhealthy alcohol use in patients with chronic liver disease.

Hepatology (Baltimore, Md.)·2026
Same journal

AASLD AST NASPGHAN Practice Guideline on pediatric liver transplantation: Candidate evaluation.

Hepatology (Baltimore, Md.)·2026
Same journal

H4K12 lactylation drives TREM2high macrophages differentiation in liver fibrosis.

Hepatology (Baltimore, Md.)·2026
Same journal

Good vibrations: Using VCTE to predict hepatic decompensation in MASLD.

Hepatology (Baltimore, Md.)·2026
Same journal

One size does not fit all: Global variability in noninvasive testing for MASLD.

Hepatology (Baltimore, Md.)·2026
See all related articles

Related Experiment Video

Updated: May 8, 2026

Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer
08:37

Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer

Published on: November 15, 2024

Exploring the interaction between metabolic dysfunction and alcohol-associated hepatitis: A global study.

Vania Cari1, María Ignacia Perez1, Ignacio Tellez1

  • 1Departamento de Medicina Interna, Escuela de Medicina, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

Hepatology (Baltimore, Md.)
|May 6, 2026
PubMed
Summary
This summary is machine-generated.

Cardiometabolic risk factors (CMRF) did not increase mortality in severe alcohol-associated hepatitis (AH). While higher BMI showed a slight survival benefit, it may indicate better nutrition rather than a protective effect in AH patients.

Keywords:
alcohol use disorderalcoholic hepatitiscardiometabolic risk factorscirrhosismetabolic syndromeobesity

More Related Videos

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish
10:45

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish

Published on: May 25, 2017

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
05:12

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

Related Experiment Videos

Last Updated: May 8, 2026

Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer
08:37

Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer

Published on: November 15, 2024

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish
10:45

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish

Published on: May 25, 2017

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
05:12

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

Area of Science:

  • Hepatology
  • Internal Medicine
  • Metabolic Syndrome

Background:

  • Cardiometabolic risk factors (CMRF) are studied in steatotic liver disease, but their impact on alcohol-associated hepatitis (AH) severity and mortality is unclear.
  • This study aimed to evaluate the influence of CMRF on mortality in patients hospitalized with severe AH.

Purpose of the Study:

  • To investigate the association between cardiometabolic risk factors and mortality in patients with severe alcohol-associated hepatitis.
  • To determine if CMRF independently predict mortality in this patient population.

Main Methods:

  • A multinational prospective cohort study included 936 hospitalized patients with severe AH across 32 centers in 14 countries (2015-2024).
  • Analyses utilized adjusted competing-risk models, considering age, sex, ethnicity, cirrhosis history, CMRF, corticosteroid use, MELD, and ACLF grade, with liver transplantation as a competing risk.

Main Results:

  • 46.6% of patients had at least one CMRF; common factors included diabetes (17.6%) and hypertension (16.5%).
  • Survival did not differ significantly based on CMRF status (log-rank p=0.453).
  • Higher age, greater alcohol intake, MELD score, and ACLF grade 2-3 predicted mortality, but no individual CMRF independently increased mortality. A BMI between 25-40 kg/m² was associated with modestly lower mortality.

Conclusions:

  • Metabolic dysfunction was not associated with increased mortality in severe AH.
  • A higher BMI in AH patients may reflect better nutritional status rather than a protective effect against mortality.